Nelson C.
- Country
- Spain
- Department
- Urology
Research Overview
- Phase 3 Randomized Trial of Intravesical Erdafitinib Delivery System vs. Single-Agent Chemotherapy in FGFR+ Intermediate-Risk Non-Muscle Invasive Bladder Cancer
- Evaluation of TAR-200 and Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder Without Radical Cystectomy
- Efficacy and Safety Evaluation of TAR-200 and Cetrelimab in High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guérin
Data & Insights
Has run more than one trial at 42 of 142 partner sites.
Specializations
Bladder Cancer Specialization
This investigator specializes in treating complex cases of bladder cancer, with particular expertise in both non-muscle-invasive and muscle-invasive bladder cancer variants.
- Non-muscle invasive bladder cancer (NMIBC)
- Muscle-invasive bladder cancer (MIBC)
- Carcinoma in situ (CIS)
The investigator focuses on innovative therapeutic approaches for patients who have not responded to conventional treatments.
Treatment Innovations
The investigator explores advanced therapeutic combinations including TAR-200 and cetrelimab for bladder cancer treatment.
- Combination immunotherapy approaches
- Novel drug delivery systems
- Alternative treatment strategies
Their work includes evaluating treatments for patients who are ineligible for standard surgical interventions.
Clinical Outcomes
The investigator's research focuses on measuring crucial clinical outcomes in bladder cancer treatment, including:
- Complete response rates
- Disease-free survival
- Bladder intact event-free survival
Their work emphasizes preserving bladder function while effectively treating cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.